First AD

Second AD

Two meningococcal vaccines are approved for use in children as young as 2 months, Menveo and MenHibrix. Menctra can be given to children as young as 9 months. The CDC and AAP do not recommend their routine use, but do encourage the use of meningococcal vaccines in certain situations. 

 D. Immune deficiency involving IgG production

Answer: B. Travel to western Ethiopia   

The CDC and AAP recommend the use of meningococcal vaccine in children over 2 months of age in any of 3 groups: children who have anatomic or functional asplenia; children who travel to an area where the disease is endemic; and children with a persistent complement component deficiency. Western Ethiopia is at the eastern edge of the “meningitis belt” of sub-Saharan Africa where meningococcal disease is endemic. Muslims in Saudi Arabia who make the Haaj pilgrimage are also at high risk.

Exposure to disease (option A) and immune globulin deficient states (option D) are not indications for the use of these vaccines in infants. 

Here, more about use of Menveo and MenHibrix in 


CDC. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR 

http://www.cdc.gov/mmwr/pdf/wk/mm6040.pdf

Here, find the position of the CDC and American Academy of Pediatrics on this question, followed by their joint recommendation. 

Is Meningococcal Vaccine Appropriate in a Child Younger Than 1 Year?